U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296809) titled 'SKB500 Combinations in Patients With Small Cell Lung Cancer' on Nov. 25.
Brief Summary: The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Study Start Date: Dec. 20
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer
Intervention:
DRUG: SKB500
Every 3 weeks on Day 1 of each 21-day cycle, IV infusion
DRUG: PD-L1 inhibitor
Every 3 weeks on Day 1 of each 21-day cycle, IV infusion
DRUG:...